OKYO Pharma Chief Scientific Officer Demonstrates Confidence with Strategic Share Purchase

In a move that underscores the confidence of OKYO Pharma's leadership in the company's mission and future prospects, Chief Scientific Officer Raj Patil, PhD, has purchased 3,363 ordinary shares of the company. This strategic acquisition, made on the NASDAQ exchange at $1.49 per share, brings Dr. Patil's total holding to 20,030 ordinary shares, signifying a significant investment in the company's potential.

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, is focused on developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases. With its ordinary shares listed for trading on the Nasdaq Capital Market, the company is poised to make a significant impact in the pharmaceutical industry. The decision by Dr. Patil to increase his holdings in the company comes at a pivotal time, as OKYO Pharma prepares to initiate a global Phase 3 pivotal clinical trial in the second half of this year.

The upcoming clinical trial, which will enroll approximately 111 patients, aims to evaluate the efficacy of a single-dose regimen of urcosimod for the treatment of NCP. This condition, characterized by chronic pain in the cornea, affects a significant number of individuals worldwide and currently has limited treatment options. The development of effective therapies for NCP is a critical area of focus for OKYO Pharma, and the company's commitment to advancing this field is evident in its strategic investments and research endeavors.

Dr. Patil's purchase of shares not only demonstrates his confidence in the company's future prospects but also reflects the growing interest in OKYO Pharma's mission and potential. As a clinical-stage biopharmaceutical company, OKYO Pharma is at the forefront of innovation in the pharmaceutical industry, and its dedication to developing therapies for unmet medical needs is noteworthy. The company's leadership, including Dr. Patil, plays a crucial role in driving this innovation and ensuring the successful execution of its strategic plans.

For investors and stakeholders, Dr. Patil's investment in OKYO Pharma serves as a positive indicator of the company's potential for growth and success. As the company moves forward with its clinical trials and research initiatives, its leadership's confidence in its mission and prospects is likely to have a positive impact on investor sentiment. With its strong focus on innovation and commitment to addressing unmet medical needs, OKYO Pharma is well-positioned to make a meaningful difference in the lives of patients and to achieve significant milestones in the pharmaceutical industry.

OKYO Pharma's story is one of innovation, dedication, and commitment to improving the lives of patients. With a strong leadership team, a clear strategic vision, and a focus on developing therapies for unmet medical needs, the company is poised to achieve great things. As Dr. Patil's purchase of shares demonstrates, the company's leadership believes in its potential, and this confidence is likely to resonate with investors and stakeholders. As OKYO Pharma continues to advance its mission and pursue its goals, it will be exciting to see the impact that the company can have on the pharmaceutical industry and on the lives of patients worldwide.

For further information about OKYO Pharma and its mission, please visit the company's website at www.okyopharma.com. With its strong commitment to innovation, its dedication to addressing unmet medical needs, and its focus on developing effective therapies, OKYO Pharma is a company to watch in the pharmaceutical industry.